Lipid-modifying agents under development
2011
There are now several agents tailored for improving dyslipidaemic lipid profiles that have passed the preclinical testing and are presently in clinical trials. The two major fields for these new lipid drugs are:
1.
To lower the levels of apoB-containing (atherogenic) lipoproteins, i.e. LDL, VLDL and Lp(a).
2.
To increase the levels of apoA-containing (protective) lipoproteins, i.e. HDL.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI